Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

VA reviewing millions spent outside the agency on care in Phoenix

The Arizona Republic reports that the Veterans Administration is looking into spending after noting that the system had surpassed its budget for community fee care.

24 Oct 2011

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

First step in the development of new drug combinations against diseases, conditions

The researchers found a way of identifying ideal drug combinations from billions of others which would prevent inflammation from occurring.

From The University of Manchester 24 Oct 2011

Merz presents XEOMIN clinical data on dystonia at IDS 2011

New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.

22 Oct 2011

New neuroconomics study reveals how you make decisions

New research reveals how we make decisions. Birds choosing between berry bushes and investors trading stocks are faced with the same fundamental challenge - making optimal choices in an environment featuring varying costs and benefits.

22 Oct 2011

Participants invited for DHA-rich fish oil supplement study on mental performance

A particular fish oil (omega-3) supplement has been shown to improve blood flow to the brain during mental activity and to impact on certain aspects of mental performance in young adults, according to research from Northumbria University.

21 Oct 2011

Combination of available medical tests helps identify risk of AD

With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older.

21 Oct 2011

UH scientists recommend new drug strategies for chronic diseases

Researchers at the University of Houston (UH) are recommending a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's and cardiovascular diseases.

21 Oct 2011

New metabolic pathway for controlling brain inflammation

A team led by scientists from The Scripps Research Institute has identified a new metabolic pathway for controlling brain inflammation, suggesting strategies for treating it.

21 Oct 2011

CWRU to lead Cornea Preservation Time Study

Researchers at Case Western Reserve University School of Medicine will lead a national study determining if corneas transplanted up to two weeks after donor death work as well as corneas transplanted up to one week after donor death. The National Eye Institute has awarded a $12.3 million grant to support the work.

20 Oct 2011

JHU, Eisai enter drug-discovery research collaboration for brain disorders

The Johns Hopkins University (JHU) has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer's disease.

20 Oct 2011

EMA, FDA endorse use of biomarkers in Alzheimer's drug trials

A news feature in Alzforum explains the impact of new guidelines for selecting volunteers in clinical trials of Alzheimer's drugs. The European Medicines Agency (EMA), the European counterpart to the U.S. Food and Drug Administration (FDA), has endorsed the use of biomarkers—substances in the body or measurements that serve as indicators of disease—to select patients to be included in drug trials.

20 Oct 2011

Common link between Type 2 diabetes and autism

A review of the genetic and biochemical abnormalities associated with autism reveals a possible link between the widely diagnosed neurological disorder and Type 2 diabetes, another medical disorder on the rise in recent decades.

20 Oct 2011

AAN updated guideline on how to best treat essential tremor

The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.

20 Oct 2011

FUTURAGE project to tackle Europe's ageing population over the next 10 years

An ambitious project led by researchers at the University of Sheffield is set to tackle the grand challenge of Europe's ageing population over the next 10 years.

19 Oct 2011

Melbourne Brain Centre to open on Monday

Melbourne will become a magnet for the world's best and brightest brain researchers after the official opening of the Melbourne Brain Centre at The University of Melbourne Parkville by the Premier Ted Baillieu and Federal MP Michael Danby on Monday.

19 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

UTA technology could reduce time and cost to finding a cure for Alzheimer's

Technology developed by researchers at The University of Texas at Austin could significantly reduce the time and cost to finding a cure for Alzheimer's disease and help answer one of the greatest biological questions: why do we age?

18 Oct 2011

Commercialization strategies for next-generation medicines

The Center for Biotechnology at Stony Brook University, in collaboration with Demy-Colton Life Science Advisors, and key opinion leaders from the biotech and biopharmaceutical industries, academia, medical research foundations, and investment community, has organized a two-day event to forge partnerships to accelerate the development of new treatments for some of the world's most devastating diseases affecting millions.

18 Oct 2011

Hypertension drugs might reduce occurrence of Alzheimer's

Within the next 20 years it is expected the number of people with Alzheimer's disease (AD) will double from its current figure of half a million to one million. A new study has looked at whether certain types of drugs used to treat high blood pressure, also called hypertension, might have beneficial effects in reducing the number of new cases of Alzheimer's disease each year.

18 Oct 2011